IN8bio (INAB) Stock Price, News & Analysis

Company Overview

IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline.

IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications. Its memory T cell platform targets neuroinflammation and has produced product candidates for acute ischemic stroke and Alzheimer’s disease, with preclinical and translational data supporting potential disease-modifying effects.

Headquartered in South San Francisco, California, IN8bio was previously known as INmune Bio before its name change in late 2021. The company maintains collaborations with academic and clinical institutions across the United States to advance its research programs. Led by an experienced management team with backgrounds in cell therapy and drug development, IN8bio continues to build its infrastructure for manufacturing, regulatory engagement and clinical execution in pursuit of first-in-class immunotherapies.

Key Stats

• Today's Range: $2.01 to $2.20
• 50-Day Range: $1.91 to $2.49
• 52-Week Range: $1.91 to $16.70
• Volume: 68,698 shs
• Average Volume: 48,878 shs
• Market Capitalization: $9.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $180.00
• Consensus Rating: Buy

IN8bio Stock Analysis - MarketRank™

IN8bio scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

IN8bio has a consensus price target of $180.00, representing about 8,471.4% upside from its current price of $2.10.

Amount of Analyst Coverage

IN8bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IN8bio is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IN8bio is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IN8bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently decreased by 35.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IN8bio does not currently pay a dividend.

Dividend Growth

IN8bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.18% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently decreased by 35.71%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.45

News Sentiment

IN8bio has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for IN8bio this week, compared to 1 article on an average week.

Search Interest

Only 7 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IN8bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.50% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INAB Stock Analysis - Frequently Asked Questions

How have INAB shares performed this year?

IN8bio's stock was trading at $7.7160 on January 1st, 2025. Since then, INAB shares have decreased by 72.8% and is now trading at $2.10.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.26.

When did IN8bio's stock split?

IN8bio's stock reverse split on the morning of Friday, June 6th 2025.The 1-30 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did IN8bio IPO?

IN8bio (INAB) raised $44 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.

Who are IN8bio's major shareholders?

Top institutional investors of IN8bio include BIOS Capital Management LP (9.46%), Franklin Resources Inc. (6.27%), AIGH Capital Management LLC (4.95%) and Stonepine Capital Management LLC (2.72%). Insiders that own company stock include William Tai-Wei Ho, Patrick Mccall and Jeremy R Graff.
View institutional ownership trends.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IN8bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INAB
• CIK: 1740279
• Web: www.in8bio.com
• Phone: 646-600-6438
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IN8bio: $180.00
• High Price Target: $180.00
• Low Price Target: $180.00
• Potential Upside/Downside: +8,471.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -184.97%
• Return on Assets: -126.75%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 7.03
• Quick Ratio: 7.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.00 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 4,540,000
• Free Float: 3,836,000
• Market Cap: $9.53 million
• Optionable: Not Optionable
• Beta: 0.02